New research study documents VMX-C001 for Factor Xa inhibitor reversal in commercially available assays

We are proud to share that a research study conducted by Coagulation Profile BV in collaboration with our partner VarmX BV and scientists at Maastricht University and Leiden University, has been accepted for publication in Research and Practice in Thrombosis and Haemostasis [link].

The study, entitled “Coagulation assays for assessing the bypassing of factor Xa direct oral anticoagulants using VMX-C001”, addresses an important clinical challenge, namely the need for fast and reliable anticoagulation assessments in patients treated with Factor Xa direct oral anticoagulants (DOACs), to reverse the coagulation effect in case of serious bleeding or ahead of non-elective surgery.

VMX-C001 is a recombinant human Factor X variant that is being developed as a bypassing agent for Factor Xa DOACs by VarmX BV [website]. The study team used two commercially available coagulation assays, dilute prothrombin time (dPT) and dilute Russell’s viper venom time (dRVVT), to show that VMX-C001 was able to fully restore normal coagulation, with strong correlation between clotting times and drug concentrations. Both assays proved reliable both under laboratory conditions and when used on plasma samples from healthy subjects and elderly nursing home residents treated withFactor Xa DOACs. In their conclusions, the study team suggest that the two assays can be used as surrogate endpoints in the continued clinical development of VMX-C001, as well as for monitoring the therapeutic effect of Factor Xa DOACs and rescue agents.

At Coagulation Profile, we are proud to contribute our analytical expertise to research that advances safer, faster solutions for managing anticoagulation and optimising patient care. This work reflects our ongoing commitment to scientific excellence in the fields of thrombosis, haemophilia and vascular biology. Find out how your development programme can benefit from our broad experience and comprehensive knowledge by contacting us at info@coagulationprofile.com or visiting www.coagulationprofile.com.

Reference:

Nagy M, Gomes T, van Oerle R, Hackeng T, Magdelijns F, Henskens Y, Reitsma P, Short G, Spronk H, Verhoef D. Coagulation assays for assessing the bypassing of factor Xa direct oral anticoagulants using VMX-C001. Research and Practice in Thrombosis and Haemostasis 2026 (In press).